RC10| 99% High Purity | CAS 898757-96-5 Peptide | Retatrutide 5mg+cagrilintide 5mg | 10mg

Methanone, (3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-

Methanone,(3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-

898757-96-5

C23H27NO3

InChIKey=YCBQLPPQIKUZLF-UHFFFAOYSA-N

365.46500

365.47

DTXSID60642864

Bulk Drug Intermediates

38.77000

3.81120

1.19g/cm3

533.7ºC at 760 mmHg

276.6ºC

1.606

Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

Investigational — Phase 3 (REDEFINE program, CagriSema combination)

A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.

Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

NCT05249895; NCT05249882

PubChem

MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation

Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.